Following resolution using SDS-PAGE electrophoresis and transfer to nitrocellulose membranes, blocking of non-specific binding was carried out in 5% (w/v) bovine serum albumin diluted in 1x tris buffered saline containing 0

Following resolution using SDS-PAGE electrophoresis and transfer to nitrocellulose membranes, blocking of non-specific binding was carried out in 5% (w/v) bovine serum albumin diluted in 1x tris buffered saline containing 0. 05% (v/v) Tween 20. protein measured by real time quantitative polymerase chain reaction and Western blot analysis of the excised tumour tissue. Neither the oxygen saturated water nor argon nanobubbles produced a statistically significant change inHIF1expression at the transcriptional level. In contrast, a reduction of 75% and 25% in the transcriptional and translational expression ofHIF1respectively (p <0. 001) was found for the animals receiving the oxygen nanobubbles. This magnitude of reduction has been shown in previous studies to be commensurate with an improvement in outcome with both radiation and drug-based treatments. In addition , there was a significant reduction in the expression of vascular endothelial growth factor (VEGF) in this group and corresponding increase in the expression of arrest-defective protein 1 homolog A (ARD1A). == Introduction == Hypoxia, i. e. a reduction in dissolved oxygen concentration below physiologically normal levels, has been identified as playing Acolbifene (EM 652, SCH57068) a critical role in the progression of several diseases, including many types of cancer [1]. In solid tumours, it arises as a consequence of the rapid proliferation and atypical vasculature of cancerous tissue. This results in the development of areas in which oxygen demand outstrips supply [2]. Once a hypoxic environment develops within a tumour, cell populations become resistant to many conventional chemotherapeutic agents through a variety of adaptive survival mechanisms [3]. Similarly, hypoxia can have a significant influence upon the effectiveness of radiotherapy, since radiation induced damage requires the formation of reactive oxygen species, which is inhibited in the absence of oxygen [4]. Consequently hypoxia is now recognised as a key determinant of successful cancer treatment [4]. Strategies for treating hypoxia have included the development of hypoxia-selective drugs [5] and radiosensitisers such as nimorazole [6] as well as methods for directly increasing blood oxygenation, e. g. hyperbaric oxygen therapy [7], pure oxygen or carbogen breathing, ozone therapy [8], hydrogen peroxide injections [9] and administration of suspensions of oxygen carrier liquids [10]. To date, Acolbifene (EM 652, SCH57068) however , these approaches have delivered limited success owing to lack of proven efficacy and/or unwanted side effects [11]. Gas microbubbles, stabilised by a biocompatible shell have been in use as ultrasound contrast agents for several decades and have Acolbifene (EM 652, SCH57068) also been investigated as an alternative means of oxygen delivery [12]. Recent studies have demonstrated that peritoneal or intratumoral injection of oxygen-loaded microbubbles can be used to increase systemic oxygen levels [13] and substantially increase the efficacy of cancer treatment in animal models [14]. Encouragingly, no adverse side effects were observed in these studies; however , the Rabbit polyclonal to DCP2 risks Acolbifene (EM 652, SCH57068) associated with injecting high concentrations of microparticles [13] makes them unsuitable for intravenous administration and this limits their potential for clinical translation. A further route that has been explored Acolbifene (EM 652, SCH57068) involves the delivery of oxygen in the form of a stabilised foam via the stomach. Oral administration of pharmaceuticals and other therapeutic materials has considerable advantages in terms of patient acceptability, reducing the risk of infection, cost and the quantity of material that can be delivered [15]. Frequently, however , oral administration is associated with inefficient delivery and/or poor bioavailability (ibid. ). There are a number of reports in the literature of the use of foams or oxygen cocktails for the treatment of a variety of conditions [1618], but to the best of the authors knowledge there has been very little research in this area in recent years. There have been several more recent studies of oxygen saturated waters for reducing recovery times for athletes, but the clinical evidence is controversial [19]. The aim of this study was to assess the potential of a further alternative method for reducing tumour hypoxia using an orally delivered suspension of sub-micrometre sized oxygen nanobubbles stabilised by.